Medicina Legal, Psiquiatría y Patología
Departamento
ÁNGEL
PÉREZ NÚÑEZ
Profesor asociado de Ciencias de la Salud
Publicaciones en las que colabora con ÁNGEL PÉREZ NÚÑEZ (16)
2024
-
Low rCBV values in glioblastoma tumor progression under chemoradiotherapy
Neuroradiology, Vol. 66, Núm. 3, pp. 317-323
2022
-
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
EMBO molecular medicine, Vol. 14, Núm. 3, pp. e14552
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
Snorting the brain away: Cerebral damage as an extension of cocaine-induced midline destructive lesions
Journal of Neuropathology and Experimental Neurology, Vol. 79, Núm. 12, pp. 1365-1369
-
Tumor-derived pericytes driven by egfr mutations govern the vascular and immune microenvironment of gliomas
Cancer Research, Vol. 81, Núm. 8, pp. 2142-2156
2020
-
Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype
Cancers, Vol. 12, Núm. 11, pp. 1-18
-
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
Science Translational Medicine, Vol. 12, Núm. 527
2019
-
Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
Clinical and Translational Oncology, Vol. 21, Núm. 10, pp. 1413-1423
-
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma
Oxidative medicine and cellular longevity, Vol. 2019, pp. 9719730
-
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival
Neurocirugia, Vol. 30, Núm. 1, pp. 11-18
2018
-
Tumor cell vanishing with radiological changes suggesting progression in IDH-mutated diffuse astrocytoma treated only with surgery
Clinical Neuropathology, Vol. 37, Núm. 5, pp. 217-220
2017
-
Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab
Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 51-57
2016
2015
-
Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma
Molecular Cancer Therapeutics, Vol. 14, Núm. 7, pp. 1548-1558
2014
-
A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas
American Journal of Neuroradiology, Vol. 35, Núm. 6, pp. 1096-1102
2012
-
The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas
American Journal of Neuroradiology, Vol. 33, Núm. 4, pp. 701-707